A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer

Gynecologic Oncology

Volumn 132, Issue 3, 2014, Pages 573-577

  Stiekema, A ^a   Lok, C A R ^a   Kenter, G G ^a   Van Driel, W J ^a   Vincent, A D ^a   Korse, C M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

CT scan; HE4; Ovarian cancer; RMI; Ultrasound

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

AREA UNDER THE CURVE; ARTICLE; BENIGN TUMOR; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COLLOID CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ULTRASOUND;

CT-SCAN; HE4; OVARIAN CANCER; RMI; ULTRASOUND;

CA-125 ANTIGEN; FEMALE; HUMANS; LOGISTIC MODELS; MEMBRANE PROTEINS; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEINS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84896399851     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.01.005     Document Type: Article

References (26)

1. Dutch Cancer Registration (NKR). Consulted on June 27th 2012 through www.cijfersoverkanker.nl.
2. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer Int J Gynecol Obstet 95 Suppl. 1 2006 S161 S192
3. M.E. Carney, J.M. Lancaster, C. Ford, A. Tsodikov, and C.L. Wiggins A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 84 2002 36 42
4. C.C. Earle, D. Schrag, B.A. Neville, K.R. Yabroff, M. Topor, and A. Fahey et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients J Natl Cancer Inst 98 2006 172 180
5. B.A. Goff, B.J. Matthews, M. Wynn, H.G. Muntz, D.M. Lishner, and L.M. Baldwin Ovarian cancer: patterns of surgical care across the United States Gynecol Oncol 103 2006 383 390
6. B.A. Goff, B.J. Matthews, E.H. Larson, C.H. Andrilla, M. Wynn, and D.M. Lishner et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer Cancer 109 2007 2031 2042
7. I. Jacobs, and R.C. Bast Jr. The CA 125 tumour-associated antigen: a review of the literature Hum Reprod 4 1989 1 12
8. I. Jacobs, D. Oram, J. Fairbanks, J. Turner, C. Frost, and J.G. Grudzinskas A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate pre-operative diagnosis of ovarian cancer Br J Obstet Gynaecol 97 10 1990 922 929
9. C. Kirchhoff, I. Habben, R. Ivell, and N. Krull A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors Biol Reprod 45 1991 350 357
10. R.G. Moore, A.K. Brown, M.C. Miller, S. Skates, W.G. Allard, and T. Verch et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol Oncol 108 2008 402 408
11. K. Huhtinen, P. Suvitie, J. Hiissa, U.J. Junnila, J. Huvila, and H. Kijari et al. Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts Br J Cancer 100 2009 1315 1319
12. L.J. Havrilensky, C.M. Whitehead, J.M. Rubatt, R.L. Cheek, J. Groelke, and Q. He et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence Gynecol Oncol 110 2008 374 382
13. R.G. Moore, D.S. McMeekin, A.K. Brown, P. DiSilvestro, M.C. Miller, and W.J. Allard et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol Oncol 112 2009 40 46
14. B. Nolen, L. Velikokhatnaya, A. Marrangoni, K. De Geest, A. Lomakin, and R.C. Bast Jr. et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass Gynecol Oncol 117 2010 440 445
15. M. Montagnana, G. Lippi, O. Ruzzenente, V. Bresciani, E. Danese, and S. Scevarolli et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass J Clin Lab Anal 23 2009 331 335
16. Z. Yurkovetsky, S. Skates, A. Lomakin, B. Nolen, T. Pulsipher, and F. Modugno et al. Development of a multimarker assay for early detection of ovarian cancer J Clin Oncol 28 2010 2159 2166
17. T. Van Gorp, I. Cadron, E. Despierre, A. Daemen, K. Leunen, and F. Amant et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm Br J Cancer 104 2011 863 870
18. R.G. Moore, M. Jabre-Raughley, A.K. Brown, K.M. Robison, M.C. Miller, and W.J. Allard et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass Am J Obstet Gynecol 203 2010 228.e1 228.e6
19. P.A. van Noord, J.S. Dubas, M. Dorland, H. Boersma, and E. te Velde Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity and lifestyle factors Fertil Steril 68 1997 95 102
20. L. Hertlein, P. Stieber, A. Kirschenhofer, K. Krocker, D. Nagel, and M. Lenhard et al. Human epididymis protein 4 in benign and malignant diseases Clin Chem Lab Med 50 12 2012 2181 2188
21. B. Nagy Jr., Z.T. Krasznai, H. Balla, M. Csoban, P. Antal-Szalmas, and Z. Hernadi et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease Ann Clin Biochem 49 Pt 4 2012 377 380
22. Elisabeth R. DeLong, David M. DeLong, and Daniel L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 3 1988 837 845
23. M.A. Karlsen, N. Sandhu, C. Hogdall, I.J. Christensen, L. Nedergaard, and L. Lundvall et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass Gynecol Oncol 127 2012 379 383
24. F. Jacob, M. Meier, R. Caduff, D. Goldstein, T. Pochechueva, and N. Hacker et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting Gynecol Oncol 121 2011 487 491
25. R.G. Moore, M.C. Miller, E.E. Eklund, K.H. Lu, R.C. Bast Jr., and G. Lambert-Messerlian et al. Serum levels if the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age Am J Obstet Gynecol 206 4 2012 [349 e1-7]
26. J.M.G. Bonfrer, C.M. Korse, R.A. Verstraeten, G.J. van Kamp, G.A. Hart, and P. Kenemans Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of reference value Clin Chem 1997 491 497